• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival Data - And What's Next

    Simply Wall St·09/04/2026 09:27:07
    語音播報
    • Akeso Inc., Summit Therapeutics’ partner, recently reported that ivonescimab plus chemotherapy delivered statistically significant overall survival, progression-free survival, and response rate benefits over durvalumab plus chemotherapy in a Phase III biliary tract cancer trial conducted in China.
    • These results, together with earlier positive overall survival data for ivonescimab versus pembrolizumab in advanced NSCLC, highlight growing clinical validation for Summit’s lead asset across multiple difficult-to-treat tumor types.
    • We’ll now examine how ivonescimab’s survival gains versus established checkpoint regimens could reshape Summit Therapeutics’ investment narrative and risk profile.

    The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Summit Therapeutics Investment Narrative Recap

    To own Summit Therapeutics, you need to believe ivonescimab can earn regulatory approvals and meaningful uptake across several solid tumors before cash burn becomes a constraint. The new positive HARMONi‑GI1 biliary tract cancer data strengthens the broader clinical story but does not obviously change the key near term catalyst, which remains the U.S. FDA decision on the HARMONi BLA, or the central risk around heavy spending without current product revenue.

    Among recent updates, the accepted BLA for ivonescimab plus chemotherapy in EGFR‑mutant NSCLC, with a PDUFA date of November 14, 2026, is most relevant here. The BTC and prior NSCLC survival wins from Akeso add external clinical context as the FDA weighs whether HARMONi’s data meet its bar for overall survival benefit, making the regulatory outcome an even more important reference point for how much value investors ultimately ascribe to Summit’s extensive Phase III program.

    Yet while these trial wins are encouraging, investors should also be aware that...

    Read the full narrative on Summit Therapeutics (it's free!)

    Summit Therapeutics' narrative projects $897.3 million revenue and $169.7 million earnings by 2029. This implies an earnings increase of about $1.37 billion from -$1.2 billion today.

    Uncover how Summit Therapeutics' forecasts yield a $28.36 fair value, a 66% upside to its current price.

    Exploring Other Perspectives

    SMMT 1-Year Stock Price Chart
    SMMT 1-Year Stock Price Chart

    The most bearish analysts painted a far tougher picture, assuming only about US$15.9 million of revenue and roughly US$2.8 million of earnings by 2029, so you should weigh these cautious expectations against ivonescimab’s expanding survival data and consider how fresh results like HARMONi GI1 might shift both the upside case and the risk of further dilution.

    Explore 4 other fair value estimates on Summit Therapeutics - why the stock might be worth over 7x more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Seeking Other Investments?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.